GlassScriptPhysician profile
Patrick V Mcconnell
NPI 1215904818
$1,368.28
in general payments reported to CMS, 2019-2025
18 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $63.45 · 2023: $313 · 2024: $299 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $294.08 | 2021-2025 | |
| Amgen INC. | $219.11 | 2021-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $169.58 | 2023-2025 | Spravato |
| Novo Nordisk INC | $142.97 | 2021-2024 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $131.49 | 2025 | Austedo Xr |
| Amarin Pharma, INC. | $97.33 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.73 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $62.27 | 2021 | |
| Horizon Therapeutics Plc | $24.96 | 2021 | |
| Lilly USA, LLC | $23.43 | 2023 | Mounjaro |
| Nestle Healthcare Nutrition INC. | $18.19 | 2021 | |
| Esperion Therapeutics, INC. | $15.96 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $15.58 | 2021 | |
| Almatica Pharma LLC | $15.04 | 2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $14.78 | 2023 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2021 | |
| Philips North America LLC | $14.23 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.85 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.